What if we could give the body instructions to produce its own drugs?
This would be nothing less than a new era in drug therapy and is exactly what messenger RNA (mRNA) could achieve.
At ACCANIS, we develop innovative therapeutics for the treatment of common, localized diseases using mRNA (Messenger RNA).
Each cell in your body uses mRNA to translate genetic information into proteins. ACCANIS´ innovative technology takes advantage of this natural mechanism in order to enable uniquely-effective, on-demand therapeutics.
mRNA is a new drug format offering unprecedented features and opportunities. It allows for the expression of fully human proteins generating distinct advantages over current treatment modalities. The human proof of concept for mRNA medications has been achieved by Pfizer/Biontech and Moderna with their Covid-19 vaccines. ACCANIS is developing proprietary, mRNA-based therapeutics derived from its platform technology asset called RNAVIENNATM. So far, we have developed two mRNA assets from its platform.
One of them is encoding for interferon-alpha (IFN-a) for the treatment of actinic keratosis and non-melanoma skin cancer.The second one expresses fibroblast growth factor 2 (FGF-2). ACCANIS´ FGF-2 mRNA will be used as a potent anti-aging/skin rejuvenation agent. also, atrophic scars will be treated with the same molecule.Our mRNAs are applied as "naked" mRNA. Higher COGS- and/or license fee generating carriers like LNPs are not necessary.
messenger RNA Technology Gave Us the First COVID-19 Vaccines.
The ability to code messenger RNA will transform medicine.
Actinic keratosis: 2017, $7.2 bn; 2026, $10.3 bn.
Non-melanoma skin cancer: 2017, $3.4 bn; 2026, $5.4 bn.
Skin rejuvenation/Anti-aging: 2017, $16.4 bn; 2026: $23.8 bn.
Atrophic scars: 2017, $4.7 bn; 2026: $6.7 bn.